Search results for "Von willebrand"

showing 10 items of 90 documents

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and s…

2015

The mobilization pattern and functionality of endothelial progenitor cells after an acute ischemic event remain largely unknown. The aim of our study was to characterize and compare the short- and long-term mobilization of endothelial progenitor cells and circulating endothelial cells after acute myocardial infarction or atherothrombotic stroke, and to determine the relationship between these cell counts and plasma concentrations of vascular cell adhesion molecule (VCAM-1) and Von Willebrand factor (VWF) as surrogate markers of endothelial damage and inflammation. In addition, we assessed whether endothelial progenitor cells behave like functional endothelial cells. We included 150 patients…

AdultMaleVascular Endothelial Growth Factor ACD31medicine.medical_specialtyTime FactorsMyocardial InfarctionCD34Vascular Cell Adhesion Molecule-1Cell CountInflammationSeverity of Illness IndexEndothelial progenitor cellImmunophenotypingchemistry.chemical_compoundVasculogenesisRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesProgenitor cellMolecular BiologyCells CulturedAgedEndothelial Progenitor Cellsbusiness.industryEndothelial CellsMiddle AgedStrokeVascular endothelial growth factorPhenotypeEndocrinologychemistryCase-Control StudiesCardiologyCD146Femalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Molecular and Cellular Cardiology
researchProduct

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

2007

Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous b…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentHemorrhagePostoperative HemorrhageGastroenterologyVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildProspective cohort studyAgedAged 80 and overHemostasisBleeding episodesFactor VIIIbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseSurgeryClinical trialvon Willebrand DiseasesCoagulationChild PreschoolHemostasisConcomitantbiology.proteinFemaleSafetybusinessJournal of Thrombosis and Haemostasis
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Association between platelet glycoprotein Ib-alpha and myocardial infarction: results of a pilot study performed in male and female patients from Sic…

2007

Myocardial infarction (AMI) is a complex multifactorial disorder. Platelet adhesion and thrombosis are pivotal events in the development of atherosclerotic lesions. Occlusive thrombus is almost exclusively initiated by plaque rupture and adhesion of platelets to subendothelial von Willebrand factor (vWf) by its specific platelet receptor, the alpha-chain of glycoprotein (GP) Ib-IX-V complex of the human platelet-specific antigens (HPA). Two polymorphisms have been reported in the sequence of GPIb-alpha. The first, a C/T transition at nucleotide 1018 results in an amino acid dimorphism (Thr/Met) at residue 145 of GPIb-alpha, which is located within the vWF-binding domain of the receptor. The…

AdultMalemedicine.medical_specialtyKozak consensus sequenceMyocardial InfarctionPilot ProjectsPlatelet membrane glycoproteinGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAntigenVon Willebrand factorGene FrequencyPolymorphism (computer science)Internal medicinevon Willebrand FactormedicineHumansPlateletSicilyAllelesPolymorphism Geneticbiologybusiness.industryGeneral NeurosciencePlatelet Glycoprotein GPIb-IX ComplexMiddle AgedEndocrinologyCoagulationPlatelet Glycoprotein GPIb-IX ComplexCase-Control StudiesImmunologybiology.proteinFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Subcortical ischaemic changes in young hypertensive patients: frequency, effect on cognitive performance and relationship with markers of endothelial…

2007

Information on subcortical ischaemic changes (SIC) in young hypertensive patients is scarce. We evaluated the frequency of SIC at magnetic resonance imaging (MRI), the possible effect on cognition of these patients, and the role of plasma markers known as indicators of endothelial and haemostatic activation. Inclusion criteria were age <or=54 years, hypertension for at least 2 years and absence of cerebrovascular disease or other conditions possibly related to SIC. Patients with SIC at MRI and two control groups (matched for age, sex and education) of hypertensive patients without SIC and non-hypertensive healthy subjects underwent an extensive neuropsychological examination and evaluation …

AdultMalemedicine.medical_specialtyPathologyEndotheliumNeuropsychological TestsBrain IschemiaCognitionstomatognathic systemVon Willebrand factorInternal medicinemedicineHumansAge FactorEffects of sleep deprivation on cognitive performanceEndothelial dysfunctionHemostasisbiologymedicine.diagnostic_testbusiness.industryAge FactorsNeuropsychologyBrainMagnetic resonance imagingBiomarkerHemostasiMiddle Agedmedicine.diseaseMagnetic Resonance ImagingBlood pressuremedicine.anatomical_structureNeurologyHemostasisHypertensionCardiologybiology.proteinFemaleEndothelium VascularNeurology (clinical)businessBiomarkersHumanEuropean Journal of Neurology
researchProduct

Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

2004

Abstract Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B 2 , index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite a…

AdultMalemedicine.medical_specialtyThromboxaneaspirinRadioimmunoassaychemistry.chemical_compoundThromboxane A2Von Willebrand factorDouble-Blind MethodInternal medicinetype 2 diabetes triellitusvon Willebrand Factormedicineplatelet activationHumansPlateletPlatelet activationAgedRetrospective StudiesAspirinbiologyDose-Response Relationship DrugMiddle AgedSalicylatesThromboxane B2Thromboxane B2triflusalP-SelectinEndocrinologychemistryDiabetes Mellitus Type 2biology.proteinTriflusalFemaleCardiology and Cardiovascular MedicineBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up Studies
researchProduct